Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma Irene Ghobrial, MD from Dana-Farber Cancer Institute, Boston, MA, chairs a discussion on the detection of minimal residual disease (MRD) in multiple myeloma (MM) patients during the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria. The expert panel, featuring Hervé Avet-Loiseau, MD, […]

Read More